Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
![Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari. image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fcommunity%25252Fpublic%25252Fshared%25252FParameswarn_Hari2018-231x300_ea0c4679-9df8-4ed8-a63a-66a5a36bdc72.jpg%253Falt%253Dmedia)
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Event Description
Dr. Parameswaran Hari, MD, MRCP, MS
Interview date: January 24, 2014
Who should consider an allogenic (donor) transplant? You may be surprised. While it is not for everyone, Dr. Hari describes myeloma patients who are to benefit the most from allogeneic translpant: young, high-risk patients, patients that relapse quickly (in 1-2 years after treatment) or plasma cell leukemia patients. Allo transplants are the oldest immunotherapy in in the book - the donor's immune cells find and kill the myeloma cells. Dr. Hari shares how safety has jumped in recent years from prior dismal rates to a 5% mortality rate in young patients because of new transplant methods and new drugs. Dr. Hari describes the "mini" allo transplant, the "reduced intensity" allo transplant and why you may want to do an auto then an allo transplant in tandem. He previews a large, multi-center study that will open in a few months for high risk patients or those with a single relapse using the allo transplant with or without an oral proteasome inhibitor. For those who are struggling to find a matching donor in the Be The Match registry, Dr. Hari describes a very interesting early study that uses a family half-matched family donor (like a sibling) with natural killer cells - what looks like a very effective immunotherapy one-two punch to kill myeloma cells. He emphasizes (again!) that we should do deep diagnostic testing at a myeloma academic center so we will be positioned later to learn which treatments are better for which types of patients. If we start treatment without correct diagnostics, that information is lost.
The live mPatient Myeloma Radio podcast with Dr. Parameswaran Hari
Schedule & Agenda
Speakers & Moderators
![The panelist Paramesewaran Hari, MD, MS](https://storage.googleapis.com/crowdnews-media-library/2019/09/parmeswaran-hari-200x200.jpg)
Parameswaran Hari, MD, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief of the Division of Hematology and Oncology in the Department of Medicine. In 2013, Dr. Hari received the Grassroots Champion for Patient Access award from the Association of Community Cancer Centers for promoting clinical efforts in the field of blood cancers. Dr. Hari had fellowships in Internal Medicine and Hematology from the United Kingdom and Medical Oncology and Transplantation at the Medical College of Wisconsin. He earned his MD from the Jawaharlal Institute of Post Graduate Medicine in India and his MBBS from the University of Kerala in India.
![The panelist Jennifer Ahlstrom](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2FJenny%20Bio%20300x300.jpg?alt=media)
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)